Biotechnology News and Research

RSS

German hospital adopts Luminex new diagnostic assay to manage current E.coli outbreak

Luminex Corporation and the Kliniken der Stadt Koln, Institute of Pathology and Institute for Hygiene today announced that Luminex's newly released xTAG Gastrointestinal Pathogen Panel (GPP) is being used successfully as a first-line screen for patients at Kliniken der Stadt Koln suspected of having an E. coli infection.

From Luminex 10 Jun 2011

LGL to host third annual pharmacogenetic conference on 8-9th November 2011

London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, is pleased to announce that its third annual pharmacogenetic conference will feature top-level presentations from players in all parts of the healthcare chain.

10 Jun 2011

Nordion to disclose details of new GammaFIT modular irradiator system at IMRP 2011

Nordion Inc., a leading provider of products and services to the global health science market, today announced it will be unveiling details of its new Flexible Irradiation Technology (GammaFIT) modular irradiator system.

10 Jun 2011

FDA CDER, ChanTest enter research collaboration agreement

ChanTest Corporation has entered into a research collaboration with the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER).

10 Jun 2011

European Bioinformatics Institute drives genomics research with GÉANT

The European Molecular Biology Laboratory’s European Bioinformatics Institute (EMBL-EBI), which hosts the world’s largest public collection of molecular biology databases, is using the pan-European GÉANT research network and JANET, the UK research network, to help biologists share vital data across the globe.

9 Jun 2011

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced the expansion of sites for its Phase II clinical trial of ICT-107. ICT-107 is the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM).

9 Jun 2011

Celerion earns ANVISA certification to conduct clinical research operations in Belfast, Lincoln

Celerion, the premier provider of innovative early stage drug development solutions, is pleased to announce that its clinical research operations in Belfast, Northern Ireland UK, and its clinical research and bioanalytical services operations in Lincoln, Nebraska USA, have been certified by the Brazilian National Health Surveillance Agency.

9 Jun 2011

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

Repligen Corporation today reported results for the fourth quarter and fiscal year 2011, ended March 31, 2011.

9 Jun 2011

JDRF, Selecta Biosciences partner to develop type 1 diabetes vaccine

The Juvenile Diabetes Research Foundation (JDRF) and Selecta Biosciences, Inc. announced today that they have established a research collaboration to support Selecta's development of a vaccine technology, which may subsequently help to better treat and potentially prevent type 1 diabetes.

9 Jun 2011

PDL revises revenue guidance for second quarter 2011 to $122M

PDL BioPharma, Inc. (PDL) today revised its guidance for the second quarter ending June 30, 2011, to approximately $122 million, as compared with actual results of $120 million for the second quarter of 2010, an anticipated one percent year-over-year increase.

9 Jun 2011

UAB acquires first cell-processing workstation from SANYO

The University of Alabama at Birmingham has taken a significant step toward making sophisticated cell therapy a part of patient care with its acquisition of the first cell-processing workstation (CPWS) from SANYO North America Corporation (SANYO) in the United States.

9 Jun 2011

Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that Seattle Genetics has exercised an option to co-develop a second antibody-drug conjugate (ADC) under the companies' existing ADC collaboration agreement.

9 Jun 2011

Metabolomics analysis shows 3IS as early predictive, sensitive biomarker of acute kidney injury

Metabolon, Inc., the leader in metabolomics, biomarker discovery and analysis, announces the publication of "Metabolomics Analysis Reveals Elevation of 3-Indoxyl Sulfate in Plasma and Brain during Chemically-induced Acute Kidney Injury in Mice: Investigation of Nicotinic Acid Receptor Agonists", in Toxicology and Applied Pharmacology.

9 Jun 2011

Thymosin beta 4 can transform adult epicardial stem cells into functional heart muscle

RegeneRx Biopharmaceuticals, Inc. has announced that thymosin beta 4 (Tβ4) can activate a unique subpopulation of resident adult epicardial stem cells such that they recapture embryonic potential, proliferate, migrate and differentiate into functional heart muscle (cardiomyocytes), according to a research paper published online today in Nature.

9 Jun 2011

Clovis, Avila select CO-1686 drug candidate for EGFR Mutant-Selective Inhibitor program

Avila Therapeutics, Inc. a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced that it has achieved a significant goal in its alliance with Clovis Oncology, Inc.

9 Jun 2011

Skin cell-derived CGRP-beta may cause chronic pain

A new study may explain why only 50% of patients experiencing chronic nerve pain achieve even partial relief from existing therapeutics. The study, published in the June 6 online version of the international research journal PAIN, reveals that certain types of chronic pain may be caused by signals from the skin itself, rather than damage to nerves within the skin, as previously thought.

9 Jun 2011

Neurologix reports new results from NLX-P101 Phase 2 trial against Parkinson's disease

Neurologix, Inc. announced today several new results from the Company's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease (PD) as part of a comprehensive presentation of study findings to the National Institutes of Health (NIH) Recombinant DNA Advisory Committee.

9 Jun 2011

Valuable insight into how people develop B-cell lymphoma

Researchers from the University of Sheffield have discovered valuable insight into how people develop B-cell lymphoma, one of the most common cancers in the UK.

9 Jun 2011

UAB first in U.S. with cell-processing workstation

8 Jun 2011

Positive results from RXi's NeuVax-trastuzumab Phase 2 trial on breast cancer presented at ASCO

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, presented Phase 2 efficacy results for NeuVax in combination with trastuzumab at the American Society of Clinical Oncology (ASCO) annual meeting.

8 Jun 2011

Biotechnology News and Research

German hospital adopts Luminex new diagnostic assay to manage current E.coli outbreak

LGL to host third annual pharmacogenetic conference on 8-9th November 2011

Nordion to disclose details of new GammaFIT modular irradiator system at IMRP 2011

FDA CDER, ChanTest enter research collaboration agreement

European Bioinformatics Institute drives genomics research with GÉANT

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

Celerion earns ANVISA certification to conduct clinical research operations in Belfast, Lincoln

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

JDRF, Selecta Biosciences partner to develop type 1 diabetes vaccine

PDL revises revenue guidance for second quarter 2011 to $122M

UAB acquires first cell-processing workstation from SANYO

Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

Metabolomics analysis shows 3IS as early predictive, sensitive biomarker of acute kidney injury

Thymosin beta 4 can transform adult epicardial stem cells into functional heart muscle

Clovis, Avila select CO-1686 drug candidate for EGFR Mutant-Selective Inhibitor program

Skin cell-derived CGRP-beta may cause chronic pain

Neurologix reports new results from NLX-P101 Phase 2 trial against Parkinson's disease

Valuable insight into how people develop B-cell lymphoma

UAB first in U.S. with cell-processing workstation

Positive results from RXi's NeuVax-trastuzumab Phase 2 trial on breast cancer presented at ASCO

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News